Here is a selection of this week's latest news from around the world
 |
 |
|
NHS England to fund Actelion's UptraviActelion has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH) can now be treated with Uptravi (selexipag). To read more follow this PharmaTimes link |
Bristol-Myers to buy Celgene in industry-shaking $74B dealBristol-Myers Squibb will acquire Celgene in a $74 billion cash-and-stock deal that would recast the top ranks of the pharmaceutical industry, creating a powerful company with leading positions in immuno-oncology and the treatment of blood cancers. To read more follow this BioPharmaDive link |
|
 |
 |
|
Drugmakers open new year with price increases on dozens of medicinesSeveral major drugmakers, including Allergan, Bristol-Myers Squibb and Eli Lilly, increased prices on a number of their drugs Jan. 1, holding with typical industry practice despite continuing scrutiny of rising pharmaceutical costs. To read more follow this BioPharmaDive link |
Sprycel combo gets FDA approvalThe US Food and Drug Administration has approved a new treatment for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when used in combination with chemotherapy. To read more follow this PharmaTimes link |
|
 |
 |
|
Pfizer, Merck to terminate Phase III Bavencio studyPfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio (avelumab), as the data did not support the study's initial hypothesis. To read more follow this PharmaTimes link |
Merck licenses diabetes, NASH treatment from NGMMerck & Co. exercised a licensing option with NGM Biopharmaceuticals on a monoclonal antibody being tested to treat nonalcoholic steatohepatitis (NASH) and Type 2 diabetes, the companies announced Thursday. To read more follow this BioPharmaDive link |